CNSide helps physicians develop a personalised cancer treatment plan. Credit: valelopardo / Pixabay.

Molecular diagnostic assays provider Biocept has enrolled the first participant in the FORESEE clinical trial for CNSide, its cerebrospinal fluid assay.

The first participant was enrolled at the UT Southwestern Medical Center in Texas, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A total of 40 breast or non-small cell lung cancer (NSCLC) patients with suspicious or confirmed leptomeningeal metastases (LM) are expected to be enrolled in the trial.

The prospective, multicentre FORESEE trial has been designed to assess CNSide’s performance in tracking the response of LM to treatment, as well as the impact of the assay on doctors’ treatment decisions. 

CNSide has been designed to analyse and assess cerebrospinal fluid tumour cells (CSF-TCs) and cell-free DNA (cfDNA) for certain biomarkers.  

See Also:

The Laboratory Developed Test (LDT) uses samples that are processed in Biocept’s clinical laboratory improvement amendments (CLIA)-certified and college of american pathologists (CAP)-accredited laboratory. The assay is used commercially at the physician’s discretion. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biocept chairman, interim president and CEO Sam Riccitelli said: “The FORESEE trial evaluates the medical and clinical utility, when compared to standard of care, of the CNSide laboratory test, a revolutionary technology designed to detect cells in the cerebral spinal fluid of central nervous system brain metastasis patients.

“The test can be used to detect the presence of tumour, as well as guide and monitor therapy, an area of critical need for these terminally ill patients.”

The company stated that the CNSide assay can provide doctors with better information regarding the actionable molecular information associated with a patient’s metastatic cancer.

This will help healthcare professionals to develop a personalised cancer treatment plan.